All In Biotech

NDA 213436 · Impel Pharms

Trudhesa

Dihydroergotamine Mesylate · Nasal

Last checked: Nov 19, 2026Latest source record: Sep 2, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Sep 2, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

5 Phase 3, 0 recruiting

FAERS reports

1,336

685 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of TRUDHESA with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7.1) ]. WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS See full prescribing information for complete boxed warning. Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4...

What it is approved for

From the label in effect Sep 3, 2026.

TRUDHESA is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use TRUDHESA is not indicated for the preventive treatment of migraine. TRUDHESA is not indicated for the management of hemiplegic or basilar migraine. TRUDHESA is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use: TRUDHESA is not indicated for the preventive treatment of migraine or for the management of hemiplegic or basilar migraine. ( 1 )

Mechanism: Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TRUDHESA · DIHYDROERGOTAMINE MESYLATE 0.725MG/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dihydroergotamine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective591
  • nausea395
  • off label use367
  • hyperhidrosis356
  • nightmare339
  • sedation339
  • product use in unapproved indication293
  • nephrolithiasis252
  • migraine110
  • dyspnoea88
  • nasal congestion81
  • headache64

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200516
200624
200724
200820
200915
201018
201126
201226
20132
20142
20152
20169
201718
201814
201926
202020
202167
2022172
2023237
2024181
2025181
2026219

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trudhesa (Dihydroergotamine Mesylate)

2024 spending

$5.6M

Beneficiaries

362

1,102 claims

Per beneficiary

$15,599

$783.19 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,534,222
2023$3,103,565
2024$5,646,781

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 247 on PubMed

Sponsor: Impel Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.